Endo fights FTC’s “back-door” challenge
The Federal Trade Commission is using the Impax case about an alleged 2010 no-authorised-generic agreement to attack a patent settlement made just last August, Endo Pharmaceuticals said in a successful bid last week to intervene in the agency’s administrative proceeding.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10